Editorial: Molecular and immune influences in the progression of gliomas
Authors:
Open Access
- 1 February 2023
- journal article
- editorial
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 13, 1102445
Abstract
Editorial: Molecular and immune influences in the progression of gliomasKeywords
This publication has 10 references indexed in Scilit:
- Clinical implications of the 2021 edition of the WHO classification of central nervous system tumoursNature Reviews Neurology, 2022
- Regulation of autophagy as a therapeutic option in glioblastomaApoptosis, 2021
- Glial and myeloid heterogeneity in the brain tumour microenvironmentNature Reviews Cancer, 2021
- Siglecs-7/9 function as inhibitory immune checkpoints in vivo and can be targeted to enhance therapeutic antitumor immunityProceedings of the National Academy of Sciences, 2021
- Turning strength into weakness: protein degradation and autophagy as therapeutic targets in glioblastoma?Neuro-Oncology, 2021
- Diffuse Glioma Heterogeneity and Its Therapeutic ImplicationsCancer Discovery, 2021
- HERC3-Mediated SMAD7 Ubiquitination Degradation Promotes Autophagy-Induced EMT and Chemoresistance in GlioblastomaClinical Cancer Research, 2019
- EMT Regulation by Autophagy: A New Perspective in Glioblastoma BiologyCancers, 2019
- CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012Neuro-Oncology, 2015
- The prevalence of autoantibodies against cartilage intermediate layer protein, YKL-39, osteopontin, and cyclic citrullinated peptide in patients with early-stage knee osteoarthritis: evidence of a variety of autoimmune processesRheumatology International, 2004